Edition:
Deutschland

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

114.59USD
22 Feb 2018
Change (% chg)

$-2.51 (-2.14%)
Prev Close
$117.10
Open
$117.74
Day's High
$118.26
Day's Low
$114.09
Volume
603,878
Avg. Vol
715,667
52-wk High
$149.17
52-wk Low
$96.18

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Buy/Sell

Sell Hold Buy
1.71 Mean rating from 21 analysts

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13

* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018

PRESS DIGEST -Wall Street Journal - Jan 3

Jan 3 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Alexion, Elliott to jointly look for new director

Jan 2 Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.

BRIEF-Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

* ALEXION AND ELLIOTT AGREE TO COLLABORATE ON IDENTIFYING A NEW BOARD MEMBER

BRIEF-Soliris(Eculizumab) Gets Marketing Authorization In Japan For Treatment Of Patients With gMG

* SOLIRIS® (ECULIZUMAB) RECEIVES MARKETING AUTHORIZATION IN JAPAN FOR THE TREATMENT OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG) Source text for Eikon: Further company coverage:

Elliott Management seeks changes at Alexion - NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals , is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

US STOCKS-Wall Street closes higher after payrolls report

* Dow up 0.49 pct, S&P 500 up 0.55 pct, Nasdaq up 0.40 pct (Updates to market close)

US STOCKS-November payrolls report lifts Wall St

* Dow up 0.34 pct, S&P 500 up 0.43 pct, Nasdaq up 0.46 pct (Updates to mid-afternoon, changes byline)

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.19%
Rohstoffe +0.14%
Industrie +0.09%
Konjunktur abhängige Waren & Dienstleistungen -0.10%
Konjunktur unabhängige Waren & Dienstleistungen +0.03%
Finanzindustrie -0.01%
Pharma +0.01%
Technologie +0.09%
Telekommunikation +0.09%